Oncologist criticises NICE for not recommending wider use of MRI in prostate cancerBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g174 (Published 10 January 2014) Cite this as: BMJ 2014;348:g174
- Geoff Watts
Guidance issued last week by the National Institute for Health and Care Excellence (NICE) on the diagnosis and management of prostate cancer was a “missed opportunity,” said an expert on early management of the disease, because it recommended only limited use of magnetic resonance imaging (MRI) in diagnosis.
Mark Emberton, professor of interventional oncology at University College London, told a briefing on cancer organised by the UCL School of Pharmacy on 9 January that it made good sense to image the prostate before all biopsies of the organ—and not only in the more limited circumstances suggested by NICE.1
In its guidance, …
Log in using your username and password
Log in through your institution
Sign up for a free trial